CREDENCE, DAPA-CKD, EMPEROR-Reduced, and EMPEROR-Preserved all found SGLT2-Is maintained renal function and prevented progression of CKD by measuring baseline eGFR over time, and they found an early dip in trend of baseline eGFR followed by decreased decline of eGFR over time as compared to placebo [8,13,15,16]. The gene discussed is SLC5A2; the disease is chronic kidney disease.